Auris Medical

Basel, Switzerland Founded: 2003 • Age: 23 yrs
Speciality Pharma company developing novel therapies for inner ear disorders
Annual revenue - Latest available
Total funding $60.7M 4 rounds
Employees - Tracked headcount
Investors 3 Known backers
Products 4 Services tracked
Competitors 10 Brand Intelligence

About Auris Medical

Auris Medical is a company based in Basel (Switzerland) founded in 2003. Auris Medical has raised $60.68 million across 4 funding rounds from investors including Hercules Capital, Idinvest Partners and Sofinnova Partners. Auris Medical offers products and services including AM-401, AM-411, Bentrio Nasal Spray, and Inner Ear Therapeutics. Auris Medical operates in a competitive market with competitors including Lyra Therapeutics, Decibel Therapeutics, Perceive Bio, Akouos and Spiral Therapeutics, among others.

  • Headquarter Basel, Switzerland
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Altamira Therapeutics Ltd.
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $60.68 M (USD)

    in 4 rounds

  • Latest Funding Round
    $5.5 M (USD), Post-IPO

    Feb 09, 2018

  • Investors
  • Employee Count
    Not available
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Auris Medical

Auris Medical offers a comprehensive portfolio of products and services, including AM-401, AM-411, Bentrio Nasal Spray, and Inner Ear Therapeutics.

Product name locked
Category locked
Primary

Targets KRAS-driven cancer through RNA delivery technologies

Product name locked
Category locked
Locked

Addresses rheumatoid arthritis via preclinical RNA therapeutics

Product name locked
Category locked
Locked

Focuses on allergy treatments being divested

Product name locked
Category locked
Locked

Develops solutions for inner ear disorders for potential licensing

People of Auris Medical

Headcount 10-50
Employee Profiles 5
Board Members and Advisors 3
Employee Profiles
People
Covadonga Pañeda
Chief Operating Officer
People
Samuel A. Wickline
Chief Scientific Adviser
People
Marcel Gremaud
Chief Financial Officer
People
Thomas Meyer
Chairman & CEO

Unlock access to complete

Funding Insights of Auris Medical

Auris Medical has successfully raised a total of $60.68M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $5.5 million completed in February 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Auris Medical

Auris Medical has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Hercules Capital, Idinvest Partners and Sofinnova Partners.

All
Venture Fund
Investor Description Founded Year Domain Location
Venture debt financing is provided to companies in multiple sectors.
Locked Locked Locked
Sofinnova Partners is focused on life sciences and healthcare investments.
Locked Locked Locked
Equity investments are provided to low and middle market companies.
Locked Locked Locked
Premium access

Investor details for Auris Medical

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Auris Medical

Investments
Premium access

Investment portfolio details for Auris Medical

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Auris Medical

Premium access

Detailed financials for Auris Medical

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Auris Medical Comparisons

Auris Medical Primary company
Description
Speciality Pharma company developing novel therapies for inn...
Location
Basel, Switzerland
Founded Year
2003
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for Auris Medical

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Auris Medical

Auris Medical operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Lyra Therapeutics, Decibel Therapeutics, Perceive Bio, Akouos and Spiral Therapeutics, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Small molecule therapeutics for ENT diseases are developed.
Locked Locked Locked
Medicines are developed to protect, repair, and restore hearing capacity.
Locked Locked Locked
Developer of therapeutics to treat diabetes and eye diseases
Locked Locked Locked
Developer of gene therapies to restore and preserve hearing capabilities in genetically defined populations
Locked Locked Locked
Therapeutics for balance disorders and hearing loss are developed.
Premium access

Detailed competitors of Auris Medical

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Auris Medical

Premium access

Complete news archive for Auris Medical

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Auris Medical

Auris Medical was founded in 2003 and raised its 1st funding round 5 years after it was founded.

Auris Medical is headquartered in Basel, Switzerland. It is registered at Basel, Basel-stadt, Switzerland.

Auris Medical is a funded company, having raised a total of $60.68M across 4 funding rounds to date.

Auris Medical is dedicated to developing novel pharmaceutical therapies for inner ear diseases tinnitus, hearing loss and menieres disease. Pipeline includes 2 late stage candidates AM-101 for tinnitus and AM-111 for sudden deafness. Other preclinical stage candidates include AM-102 for tinnitus and AM-123 for rhinology study. Company has also developed Intratympanic injection to deliver low drug doses to inner ear and minimize systemic side effects.

Auris Medical's top competitors include Decibel Therapeutics, Lyra Therapeutics and Akouos.

Auris Medical offers AM-401, AM-411, Bentrio Nasal Spray, and Inner Ear Therapeutics.

Auris Medical has 3 investors. Key investors include Hercules Capital, Idinvest Partners, and Sofinnova Partners.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available